Ongoing Clinical Trials for Immune-Mediated Renal Disorder
This article provides detailed information about an ongoing clinical trial investigating new treatment options for immune-mediated renal disorder, a condition where the immune system attacks the kidneys. Currently, there is one clinical trial actively recruiting patients to test the safety and effectiveness of an investigational medication called ARO-C3, which aims to reduce kidney inflammation and damage.
Clinical trial locations
- Germany
Study on the Safety and Effects of ARO-C3 for Adults with Complement-Mediated Kidney Disease
This clinical trial is investigating a new treatment approach for people whose kidneys are being damaged by an overactive immune system, specifically problems with the complement pathway. The complement system normally helps protect the body from infections, but when it becomes overactive, it can mistakenly attack the kidneys, causing inflammation and damage.
Main focus and goal: The primary purpose of this study is to understand how safe ARO-C3 is for patients and how well it is tolerated by the body. Researchers will also study how the medication behaves in the body over time, measuring how it is absorbed, distributed, and eliminated. Additionally, the trial will observe changes in specific proteins in the blood that are related to the disease and monitor kidney function throughout the treatment period. This information will help determine whether ARO-C3 could become a new treatment option for people with complement-mediated kidney disease.
Investigational drug: The medication being tested is called ARO-C3, which is given as an injection under the skin. It contains an active substance known as ADS-011, a type of synthetic, small interfering RNA designed to target and reduce the overactivity of the complement system. By blocking specific components of this immune pathway, ARO-C3 aims to decrease inflammation and prevent further damage to kidney tissues.
Who can participate – inclusion criteria: The trial is looking for adults between 18 and 70 years old who have been diagnosed with complement-mediated kidney disease. To be eligible, you must:
- Be willing to provide written consent and able to attend all study visits
- Have a kidney biopsy from the last 3 to 5 years confirming your specific kidney condition
- Have ongoing kidney disease with significant protein in your urine, confirmed by recent tests
- Have kidney function at a certain level (not requiring dialysis yet)
- Have been on a stable treatment plan for at least 90 days, which may include blood pressure medications or drugs that reduce protein in urine
- Be vaccinated for certain bacteria or willing to receive vaccinations before the study starts
- Have a negative COVID-19 test or proof of vaccination
- If you can have children, agree to use effective birth control during the study and for at least 90 days after treatment ends
- Have a body mass index between 18.0 and 35.0 kg/m²
Who cannot participate – exclusion criteria: You will not be eligible for this trial if you:
- Have other serious health conditions that might interfere with the study
- Are currently in another clinical trial
- Have had recent major surgery or are planning surgery during the study
- Are pregnant or breastfeeding
- Have a history of allergic reactions to similar medications
- Have a history of drug or alcohol abuse
- Are unable to follow study procedures or attend required visits
- Have an infection requiring antibiotic treatment
- Have a condition affecting your immune system that makes you more prone to infections
- Have a history of cancer (except for certain types of skin cancer)
What happens during the trial: The study follows a structured timeline with regular monitoring. After an initial assessment to confirm eligibility, you will undergo baseline evaluations including blood tests to measure kidney function and protein levels in urine. You will then receive ARO-C3 as a subcutaneous injection, with the dosage determined based on the study protocol. Regular follow-up visits will be scheduled to monitor your health and track any side effects. Throughout the study, blood tests and other assessments will continue to evaluate changes in kidney function. At the end of the study, a final assessment will determine the overall impact of the treatment.
Summary
Currently, there is one active clinical trial investigating new treatment approaches for immune-mediated renal disorder. This trial is being conducted in Germany and focuses specifically on testing ARO-C3, an investigational medication that works by targeting the complement system to reduce kidney inflammation and damage. The study represents an important step in understanding how this new approach might help manage this serious kidney condition. Patients interested in participating should meet specific health criteria and be willing to commit to regular monitoring visits throughout the treatment period. This research aims to provide valuable information about both the safety and potential effectiveness of ARO-C3, which could lead to new treatment options for people living with complement-mediated kidney disease.
